[go: up one dir, main page]

MX2015012899A - Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9. - Google Patents

Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.

Info

Publication number
MX2015012899A
MX2015012899A MX2015012899A MX2015012899A MX2015012899A MX 2015012899 A MX2015012899 A MX 2015012899A MX 2015012899 A MX2015012899 A MX 2015012899A MX 2015012899 A MX2015012899 A MX 2015012899A MX 2015012899 A MX2015012899 A MX 2015012899A
Authority
MX
Mexico
Prior art keywords
pyrrolo
pyridine
kinase inhibitors
cdk9 kinase
compounds
Prior art date
Application number
MX2015012899A
Other languages
English (en)
Inventor
Yunsong Tong
Keith W Woods
Chunqiu Lai
Zhi-Fu Tao
Todd M Hansen
Andrew Souers
Michael L Curtin
Milan Bruncko
Xiaohong Song
Thomas Penning
Richard F Clark
Zhiqin Ji
Alan S Florjancic
Rajeev Goswami
Anthony Mastracchio
Jianchun Gong
Guidong Zhu
Omprakash Reddy Iquturi
Madhu Babu Dabbeeru
Robin R Frey
Michael MICHAELIDES
Juliem Miyashiro
Roberto M Risi
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/CN2014/000265 external-priority patent/WO2014139328A1/en
Publication of MX2015012899A publication Critical patent/MX2015012899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de Fórmula (IIa), (IIa), En donde R1, R2, R3A, R3B, R3C, R3D, R3E, y R4 y las sales farmacéuticamente aceptables de los mismos son como se definen en la especificación. Los compuestos se pueden usar como agentes en el tratamiento de enfermedades, incluyendo el cáncer. También se proporcionan composiciones farmacéuticas que comprenden uno o más compuestos de Fórmula (IIa).
MX2015012899A 2013-03-14 2014-03-13 Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9. MX2015012899A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN745DE2013 2013-03-14
US201361904842P 2013-11-15 2013-11-15
PCT/CN2014/000265 WO2014139328A1 (en) 2013-03-14 2014-03-13 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015012899A true MX2015012899A (es) 2016-06-02

Family

ID=54249678

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012896A MX2015012896A (es) 2013-03-14 2014-03-13 Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2015012899A MX2015012899A (es) 2013-03-14 2014-03-13 Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012896A MX2015012896A (es) 2013-03-14 2014-03-13 Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.

Country Status (9)

Country Link
US (1) US9796708B2 (es)
EP (2) EP2970278A4 (es)
JP (2) JP2016516713A (es)
CN (2) CN105324380A (es)
AR (1) AR101528A1 (es)
AU (2) AU2014231567A1 (es)
BR (2) BR112015023187A2 (es)
CA (2) CA2905530A1 (es)
MX (2) MX2015012896A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843872B (zh) * 2017-09-20 2022-08-30 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN111328333B (zh) * 2019-09-29 2023-10-03 烟台迈百瑞国际生物医药股份有限公司 一种酸法制备抗体药物偶联物中间体的方法及其应用
MX2022004394A (es) * 2019-10-18 2022-05-18 Lead Pharma Holding Bv Moduladores de receptor alfa relacionado con estrogenos (erra).
CN116249701B (zh) * 2020-10-12 2025-05-30 上海海雁医药科技有限公司 取代的二（吡啶-2-基）胺衍生物、其组合物及医药上的用途
WO2022135580A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN112852874B (zh) * 2021-02-04 2023-05-23 中国农业科学院兰州兽医研究所 Hdac5基因敲除的bhk-21细胞系及其构建方法和应用
CN113248496B (zh) * 2021-05-06 2022-02-11 东南大学 吡咯并吡啶类化合物及其盐及其用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN113666934B (zh) * 2021-07-28 2023-06-23 北京深度制耀科技有限公司 Cdk9激酶抑制剂
CN117343058A (zh) * 2023-10-10 2024-01-05 湖南科技大学 取代7-氮杂吲哚-3-羧酸类Mcl-1蛋白抑制剂及制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1615873A (zh) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
MX2007001399A (es) 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
EP2069341B1 (en) * 2006-09-22 2010-12-29 Glaxo Group Limited Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008049856A2 (en) 2006-10-25 2008-05-02 Ingenium Pharmaceuticals Gmbh Methods of treating pain using cdk inhibitors
EP2094681A1 (en) * 2006-12-22 2009-09-02 Novartis AG Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
KR20090130065A (ko) 2007-04-13 2009-12-17 수퍼젠, 인크. 암 또는 과증식성 장애 치료에 유용한 Ａｘｌ 키나제 억제제
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
SI2212297T1 (sl) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh Inhibitorji protein kinaz
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
IN2012CH01573A (es) * 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof

Also Published As

Publication number Publication date
US20160060257A1 (en) 2016-03-03
AU2014234077A1 (en) 2015-10-01
BR112015023356A2 (pt) 2017-07-18
EP2970264A1 (en) 2016-01-20
JP2016514113A (ja) 2016-05-19
AU2014231567A1 (en) 2015-10-01
EP2970278A1 (en) 2016-01-20
MX2015012896A (es) 2016-06-02
BR112015023187A2 (pt) 2017-07-18
US9796708B2 (en) 2017-10-24
CA2905935A1 (en) 2014-09-25
AR101528A1 (es) 2016-12-28
CN105246890A (zh) 2016-01-13
JP2016516713A (ja) 2016-06-09
CA2905530A1 (en) 2014-09-18
CN105324380A (zh) 2016-02-10
EP2970278A4 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
MX2015012899A (es) Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12016500024A1 (en) Bromodomain inhibitor
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
JOP20190090B1 (ar) مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
GEP20217286B (en) Pyridone amides as modulators of sodium channels
MX2015012431A (es) Pirrol amida como inhibidores.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
HK1198475A1 (en) Heterocyclic compounds and uses thereof
PH12017501816B1 (en) Azabenzimidazoles and their use as ampa receptor modulators
CL2014001529A1 (es) Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
IN2014DN11099A (es)
MX2015010829A (es) Compuestos terapeuticos y sus usos.
GEAP201814151A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
MX340574B (es) Imidazo pirazinas.
HK1217092A1 (zh) 治疗性化合物及其用途
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
MX2015012386A (es) Inhibidores de la cinasa cdk9.
PH12015500399A1 (en) Azaindolines
MX364859B (es) Derivados de imidazopirazinona.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.